Margaret H. Collins, MD

Staff Pathologist, Division of Pathology
Director, GI Pathology
Professor, UC Department of Pathology and Laboratory Medicine
UC Department of Pediatrics

margaret.collins@cchmc.org
Board Certified

About

Biography

I belong to a community of researchers at Cincinnati Children’s Hospital Medical Center, plus other institutions here and abroad, who are unwaveringly committed to finding cures for pediatric gastrointestinal (GI) diseases, including eosinophilic gastrointestinal disorders (EGID). This is especially important to me after meeting patients and their caregivers, witnessing the impact that EGID has on their lives and sharing their hope for a Food and Drug Administration (FDA)-approved therapy.

My research strives to improve diagnostic methods for children with GI diseases, such as EGID and inflammatory bowel disease. As a pediatric pathologist at Cincinnati Children’s, I help evaluate the efficacy of various therapies, including biologics, for pediatric patients who have EGID. I also participate in multi-institutional studies of pediatric inflammatory bowel disease.

I helped create the eosinophilic esophagitis histology scoring system (EoEHSS), which systematically evaluates esophageal biopsies obtained for eosinophilic esophagitis, the most common form of EGID. Some of the features evaluated correlate with symptoms and potentially provide new therapeutic endpoints.

Beginning in 2011, U.S. News & World Report named me one of the Top Doctors in Pathology. In 2020, I received the American Academy of Asthma, Allergy and Immunology (AAAAI) and American Partnership for Eosinophilic Disorders (APFED) award for the best EGID abstract at the AAAAI annual meeting.

Interests

Pediatric gastrointestinal pathology; eosinophilic gastrointestinal diseases; biopsy analyses; primary study endpoints; novel therapies to treat eosinophilic esophagitis in children; disorders of bowel immunity; bowel motility disorders

Services and Specialties

Colorectal Disorders, Pathology, Eosinophilic Disorders

Research Areas

Pathology, Eosinophilic Disorders

Publications

Benralizumab for eosinophilic gastritis: a single-site, randomised, double-blind, placebo-controlled, phase 2 trial. Kliewer, KL; Murray-Petzold, C; Collins, MH; Abonia, JP; Bolton, SM; DiTommaso, LA; Martin, LJ; Zhang, X; Mukkada, VA; Putnam, PE; et al. The Lancet Gastroenterology and Hepatology. 2023; 8:803-815.

Eosinophilic Esophagitis Histologic Scoring System: Correlation with Histologic, Endoscopic, and Symptomatic Disease and Clinical Use. Alexander, RG; Ravi, K; Collins, MH; Lavey, CJ; Snyder, DL; Lennon, RJ; Kassmeyer, BA; Katzka, DA; Alexander, JA. Digestive Diseases and Sciences. 2023; 68:3573-3583.

Monitoring Patients With Eosinophilic Esophagitis in Routine Clinical Practice - International Expert Recommendations. Arnim, UV; Biedermann, L; Aceves, SS; Bonis, PA; Collins, MH; Dellon, ES; Furuta, GT; Gonsalves, N; Gupta, S; Hirano, I; et al. Clinical Gastroenterology and Hepatology. 2023; 21:2526-2533.

Dupilumab verbessert die klinischen, symptomatischen, histologischen und endoskopischen Merkmale der EoE unabhängig von einer früheren Therapie mit geschluckten topischen Kortikosteroiden. Madisch, A; Bredenoord, AJ; Dellon, ES; Lucendo, AJ; Collins, MH; Sun, X; Tilton, S; McCann, E; Glotfelty, L; Shabbir, A. Zeitschrift für Gastroenterologie. 2023; 61:e396-e397.

Wirksamkeit und Sicherheit von Dupilumab über bis zu 52 Wochen bei Erwachsenen und Jugendlichen mit eosinophiler Ösophagitis: Ergebnisse aus Teil B und C der randomisierten, placebokontrollierten, dreiteiligen Phase-III-Studie LIBERTY EoE TREET. von Arnim, U; Dellon, ES; Rothenberg, ME; Collins, MH; Hirano, I; Chehade, M; Bredenoord, AJ; Lucendo, AJ; Spergel, JM; Sun, X; et al. Zeitschrift für Gastroenterologie. 2023; 61:e366-e367.

Local type 2 immunity in eosinophilic gastritis. Ben-Baruch Morgenstern, N; Shoda, T; Rochman, Y; Caldwell, JM; Collins, MH; Mukkada, V; Putnam, PE; Bolton, SM; Felton, JM; Rochman, M; et al. Journal of Allergy and Clinical Immunology. 2023; 152:136-144.

Sa1270 DUPILUMAB IMPROVES INFLAMMATORY AND REMODELING ASPECTS OF ENDOSCOPIC DISEASE ACTIVITY IN EOSINOPHILIC ESOPHAGITIS: RESULTS FROM THE PHASE 3 LIBERTY-EOE-TREET STUDY. Hirano, I; Collins, MH; Dellon, ES; Sun, X; Beazley, B; Glotfelty, L; Shabbir, A; Giannelou, A. Gastroenterology. 2023; 164:s-346.

One-food versus six-food elimination diet therapy for the treatment of eosinophilic oesophagitis: a multicentre, randomised, open-label trial. Kliewer, KL; Gonsalves, N; Dellon, ES; Katzka, DA; Abonia, JP; Aceves, SS; Arva, NC; Besse, JA; Bonis, PA; Caldwell, JM; et al. The Lancet Gastroenterology and Hepatology. 2023; 8:408-421.

Sa1274 DUPILUMAB REDUCED EOSINOPHIL COUNTS AND IMPROVED HSS GRADE AND STAGE SCORES IN PATIENTS WITH EOSINOPHILIC ESOPHAGITIS: LIBERTY-EOE-TREET PHASE 3 STUDY PARTS A AND B. Collins, MH; Dellon, ES; Pela, T; Aceves, SS; Lucendo, A; Spergel, J; Sun, X; Khodzhayev, A; Radwan, A; Jacob-Nara, JA. Gastroenterology. 2023; 164:s-347-s-348.

610 EFFICACY AND SAFETY OF BENRALIZUMAB IN ADULTS AND ADOLESCENTS WITH EOSINOPHILIC ESOPHAGITIS: RESULTS FROM THE 24-WEEK DOUBLE-BLIND PERIOD OF THE PHASE 3 MESSINA TRIAL. Rothenberg, ME; Dellon, ES; Collins, MH; Bredenoord, AJ; Hirano, I; Peterson, KA; Brooks, L; Fjallbrant, H; Grindebacke, HK; Ho, CN; et al. Gastroenterology. 2023; 164:s-115.

From the Blog

Asthma and Allergy

Artificial Intelligence Holds the Key to Diagnosing Rare Esophageal Food Allergy Disease

Margaret H. Collins, MD, Marc E. Rothenberg, MD, PhD10/25/2021

Patient Ratings and Comments

All patient satisfaction ratings and comments are submitted by actual patients and verified by a leading independent patient satisfaction company, NRC Health. Patient identities are withheld to ensure confidentiality and privacy. Only those providers whose satisfaction surveys are administered through Cincinnati Children’s Hospital Medical Center are displayed. Click here to learn more about our survey

4.6

Overall Patient Rating